Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Aspacytarabine (BST-236), a possibly less toxic form of chemotherapy being developed by Biosight for people with acute myeloid leukemia (AML), has been ... Read more
Health Canada has approved Onureg, an oral formulation of the chemotherapy azacitidine, as the first maintenance therapy for adults with acute myeloid ... Read more
Eprenetapopt (APR-246), an investigational therapy being developed by Aprea Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration for treating ... Read more
A Phase 1b study testing Mylotarg (gemtuzumab ozogamicin) plus Venclexta (venetoclax) for adults with relapsing or refractory acute myeloid leukemia (AML) is currently enrolling patients. The ... Read more
The first patient has been dosed in Immune-Onc Therapeutic’s Phase 1 clinical trial of IO-202, its lead antibody treatment candidate for advanced acute ... Read more
The Phase 2 CyFi-2 study assessing the safety and efficacy of ficlatuzumab (previously AV-299) combined with standard chemotherapy in patients with ... Read more
